Literature DB >> 18636637

Genes, brain development and psychiatric phenotypes in velo-cardio-facial syndrome.

Doron Gothelf1, Marie Schaer, Stephan Eliez.   

Abstract

Velo-cardio-facial syndrome (VCFS) has been in the focus of intensive research over the last 15 years. The syndrome represents a homogeneous model for studying the effect of a decreased dosage of genes on the development of brain structure and function and, consequently, on the emergence of schizophrenia-like psychotic disorder. In this review, we describe the psychiatric phenotype of children, adolescents, and young adults with VCFS. We redefine the concept of "behavioral phenotype" and suggest that psychosis fulfills the criteria of a behavioral phenotype of the syndrome. Identifying the risk factors for the emergence of psychosis in VCFS is a major goal of several large-scale longitudinal studies that are currently underway. We review the knowledge gained so far about risk factors for psychosis in VCFS, including early neuropsychiatric symptoms, development of brain structure and function, and the effect of a reduced dosage of genes from the 22q11 deletion region. Although the brain structure in subjects with VCFS is not drastically different from typically developing controls, newer imaging modalities that measure white matter tracts, cortical thickness, and cortical gyrification are likely to identify more subtle and specific neuroanatomical substrates of the syndrome. Among the 24 genes within the deletion region, the role of catechol-O-methyltransferase (COMT) on the VCFS phenotype has been investigated in depth. The findings suggest that because of haploinsufficiency of the COMT gene individuals with VCFS are exposed to a high level of prefrontal dopamine, and this interferes with their prefrontal cognitive functioning and may contribute to their high rate of psychosis and other psychiatric disorders. The other genes and environmental factors that shape the unique neuropsychiatric phenotype of VCFS are yet to be discovered.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18636637     DOI: 10.1002/ddrr.9

Source DB:  PubMed          Journal:  Dev Disabil Res Rev        ISSN: 1940-5529


  43 in total

Review 1.  Genomic copy number variation in disorders of cognitive development.

Authors:  Eric M Morrow
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2010-11       Impact factor: 8.829

Review 2.  The 22q11.2 microdeletion: fifteen years of insights into the genetic and neural complexity of psychiatric disorders.

Authors:  Liam J Drew; Gregg W Crabtree; Sander Markx; Kimberly L Stark; Florence Chaverneff; Bin Xu; Jun Mukai; Karine Fenelon; Pei-Ken Hsu; Joseph A Gogos; Maria Karayiorgou
Journal:  Int J Dev Neurosci       Date:  2010-10-08       Impact factor: 2.457

Review 3.  The 22q11.2 deletion syndrome as a window into complex neuropsychiatric disorders over the lifespan.

Authors:  Rachel K Jonas; Caroline A Montojo; Carrie E Bearden
Journal:  Biol Psychiatry       Date:  2013-08-28       Impact factor: 13.382

4.  COMT and anxiety and cognition in children with chromosome 22q11.2 deletion syndrome.

Authors:  Vandana Shashi; Timothy D Howard; Matcheri S Keshavan; Jessica Kaczorowski; Margaret N Berry; Kelly Schoch; Edward J Spence; Thomas R Kwapil
Journal:  Psychiatry Res       Date:  2010-05-20       Impact factor: 3.222

5.  Altered Brain Structure-Function Relationships Underlie Executive Dysfunction in 22q11.2 Deletion Syndrome.

Authors:  Rachel K Jonas; Maria Jalbrzikowski; Caroline A Montojo; Arati Patel; Leila Kushan; Carolyn C Chow; Therese Vesagas; Carrie E Bearden
Journal:  Mol Neuropsychiatry       Date:  2015-12-04

Review 6.  Critical reappraisal of mechanistic links of copy number variants to dimensional constructs of neuropsychiatric disorders in mouse models.

Authors:  Noboru Hiroi
Journal:  Psychiatry Clin Neurosci       Date:  2018-03-01       Impact factor: 5.188

Review 7.  Converging levels of analysis on a genomic hotspot for psychosis: insights from 22q11.2 deletion syndrome.

Authors:  Matthew J Schreiner; Maria T Lazaro; Maria Jalbrzikowski; Carrie E Bearden
Journal:  Neuropharmacology       Date:  2012-10-23       Impact factor: 5.250

8.  Attenuated positive symptoms of psychosis in adolescents with chromosome 22q11.2 deletion syndrome.

Authors:  Joel Stoddard; Tara Niendam; Robert Hendren; Cameron Carter; Tony J Simon
Journal:  Schizophr Res       Date:  2010-01-06       Impact factor: 4.939

9.  Psychotic features as the first manifestation of 22q11.2 deletion syndrome.

Authors:  So Dahm Kook; Suk Kyoon An; Kyung Ran Kim; Woo Jung Kim; Eun Lee; Kee Namkoong
Journal:  Psychiatry Investig       Date:  2010-02-19       Impact factor: 2.505

10.  Regional cortical volumes and congenital heart disease: a MRI study in 22q11.2 deletion syndrome.

Authors:  Marie Schaer; Bronwyn Glaser; Marie-Christine Ottet; Maude Schneider; Meritxell Bach Cuadra; Martin Debbané; Jean-Philippe Thiran; Stephan Eliez
Journal:  J Neurodev Disord       Date:  2010-09-14       Impact factor: 4.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.